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Does the IMRT technique allow improvement 
of treatment plans (e.g. lung sparing) for 
lung cancer patients with small lung volume: 
a planning study
Katarzyna KomosińsKa1, Marta GiżyńsKa2, Anna ZAwADZKA2, 
Lucyna KępKa1
SUMMARY
AIM: We evaluated whether intensity-modulated radiation therapy (iMRt) may offer any advantages 
in comparison with three-dimensional conformal radiotherapy (3D-CRT) for patients with small lung 
volume (SlV).
METHODS: Treatment planning was performed for 10 NSCLC patients with the smallest lung volume 
(mean: 2241 cc) among 200 patients from our database. For each patient 3D-CRT and IMRT plans 
were prepared. The goal was to deliver 66 Gy/33 fractions, with dose constraints: mean lung dose 
(MLD)<20Gy, V20<35%; spinal cord – Dmax<45 Gy. When the plan could not meet these criteria, total 
dose was reduced. The 3D-CRT and IMRT plans were compared. We investigated: prescribed dose, 
coverage and conformity indices, MLD, V5-V65 in the lung.
RESULTS: In 4 out of 10 plans, 3D-CRT did not allow 66 Gy to be delivered, because of predicted pul-
monary toxicity. These 4 cases included 3 for which we did not reach 66 Gy with IMRT; still, for these 
3 plans the total dose was increased by an average of 9 Gy with IMRT in comparison with 3D-CRT. 
Coverage indices were similar for both techniques. Conformity indices were better for IMRT plans. 
MLD was lower in five IMRT and two 3D-CRT plans if equal doses were delivered. The decrease in MLD 
was seen for cases with large PTV and high PTV/lung volume ratio. Lung V5 was lower for all 3D-CRT 
plans, 47% vs. 57% for IMRT; V15 and above were larger for 3D-CRT
CONCLUSION: In the planning study, IMRT seems to be a promising technique for cases with SLV, es-
pecially when associated with large ptV.
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BACKGROUND
The lung is a volumetric organ at risk; its ra-
diation damage depends on the volume irra-
diated, so the maximum pulmonary volume 
should be spared from radiation. The risk for 
pneumonitis depends on the lung volume ex-
ceeding a threshold dose of 20 Gy [1]. In many 
cases of radiotherapy for lung cancer pulmo-
nary toxicity becomes a factor limiting thera-
py. Tumour, even a large one, may happen to a 
patient with small or large lung volume. In the 
case of small lung volume the ratio of tumour 
to healthy lung becomes unfavourable, which 
may preclude a possibility of delivering doses 
lower than 20 Gy to a sufficient percentage of 
lung volume. Most dosimetrists and radiation 
oncologists know that small lung volume is a 
real challenge for planning. Intensity-modu-
lated radiation therapy (IMRT) is an emerging 
cancer treatment technology, which has shown 
a capacity for better normal tissue sparing in a 
number of sites [2]. In planning studies, IMRT 
has also demonstrated a potential for reduced 
toxicity and dose escalation for lung cancer 
radiotherapy [3–5]. This incited us to investi-
gate the potential role of IMRT in treatment 
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of those challenging cases, i.e. lung cancer in 
patients with small lung volume.  
AIM
We investigated whether IMRT could give any 
advantage in comparison with standard three-
dimensional conformal radiotherapy (3D-
CRT) in patients with lung cancer and small 
lung volume in terms of sparing normal tis-
sues and/or delivering higher doses.
MATERIAL AND METHODS
Ten non-small-cell lung cancer (NSCLC) pa-
tients with the smallest lung volume were cho-
sen from 200 previously irradiated lung cancer 
patients from the database of our department. 
Mean lung volume in those 10 patients was 
2240 cubic centimetres (range: 1886 – 2634 
cc). CT scans done for previous planning 
treatment of those patients were used. Slice 
thickness on the CT scan was 5 mm. Patients 
were planned with free breathing in supine 
position on a lung board with both arms above 
the head. On each patient planning CT axial 
scans the gross tumour volume (GTV) was de-
lineated and included the primary tumour and 
any hilar or mediastinal lymph nodes with a 
short-axis diameter of at least 1 cm on the CT 
scan. Then the clinical target volume (CTV) 
was created encompassing the GTV with a 5 
mm margin within the lung without elective 
nodal irradiation. Finally, the planning target 
volume (PTV) included CTV with a 1 cm mar-
gin. Mean PTV volume was 297 cc, ranging 
from 27 cc to 611 cc. 
For each patient one 3D-CRT and one IMRT 
plan were prepared by two physicists using 
the commercial treatment planning system 
Eclipse, version 6.5 with Helios optimization 
module for IMRT optimization employing the 
Pencil Beam algorithm with Modified Batho 
for inhomogeneity correction.
We decided to design 3 coplanar beams in 
3D-CRT plans, which is our departmental 
policy. In IMRT plans there were 5 coplanar 
beams used. In 3D-CRT as well as in IMRT 
plans only 6 MV photon beams were used. 
Fig. 1 shows the typical beam arrangement 
and dose distribution for both analyzed tech-
niques. We intended to deliver 66 Gy in 33 
fractions keeping dose constraints typical for 
our department, as follows: mean lung dose 
(MLD) ≤ 20 Gy, lung V20 which is the volume 
of lung receiving a dose of 20 Gy or higher ≤ 
35%, heart V40 ≤ 50%, maximum spinal cord 
dose ≤ 45 Gy, and length of oesophagus receiv-
ing at least 60 Gy no longer than 10 cm. Keep-
ing dose constraints for the lung was a main 
planning objective. When achieving intended 
pulmonary dose restrictions was not possible, 
total dose had to be reduced.
After that, the plans were compared in 
pairs, for each patient. We took into account: 
total dose, coverage and conformity indices, 
Fig. 1. Beam arrangement and dose distribution in 3D-CRT (on the left) and in IMRT (on the right) technique
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mean lung doses (MLD), lung V5-V65 at 5 Gy 
intervals, and any relationship between PTV 
volume, lung volume and MLD.
We analysed whether it was possible to de-
liver the full total dose while keeping dose 
constraints in both studied techniques. 
Then the coverage and conformity indices 
were calculated. Coverage index (CovI) was 
defined as the volume of PTV receiving equal 
to or more than the indicated dose (Dind) di-
vided by the PTV volume. CovI=VDind(PTV)/
V(PTV). Conformity index (CI) was defined 
as the sum of value 1 plus the ratio of the nor-
mal tissue volume receiving equal to or more 
than the indicated dose to the PTV volume 
receiving equal to or more than the indicated 
dose. CI=1+[VDind(norm)/VDind (PTV)]. The 
indicated doses for CovI and CI calculations 
were selected as 95% of the total dose [6].
At the end, we made an attempt to find any 
relationship between volumes of lung, PTV 
and MLD. The correlation between size of 
PTV expressed by percentage of lung volume 
and MLD for both techniques was explored.
RESULTS
Total dose
In 6 patients a total dose of 66 Gy was suc-
cessfully achieved for both types of plans. 
Among the remaining four cases with failure 
to achieve 66 Gy it was still possible to deliver 
a higher dose using IMRT for three patients, 
on average 9 Gy higher. The mean PTV in pa-
tients receiving the full total dose was 206 cc, 
while in the whole group it was 297 cc. Fig. 
2 shows total doses achieved in consecutive 
patients. Considering all 10 cases the mean 
IMRT total dose was 3 Gy higher than the 
mean 3D-CRT total dose. In two plans (one 
3D-CRT and one IMRT) a constraint of 20 Gy 
for MLD was slightly exceeded (respectively 
by 1 Gy and 0.2 Gy), as we did not want to fur-
ther complicate the beam arrangements, and 
all other dose constraints, including V20 for 
lung, were respected. 
Coverage and conformity indices 
The best possible result for coverage index 
(CovI) was a value of 1.0. For both techniques 
in all cases, CovI was almost equal to 1.0. 
Mean result for IMRT plans was 0.995, while 
mean result for 3D-CRT plans was 0.992.
Conformity index (CI) reaching a value of 
1.0 is also the best possible. It improved sig-
nificantly with the use of IMRT, which means 
better normal tissue sparing from high doses. 
Mean CI for IMRT plans was 1.48, while mean 
CI for 3D-CRT plans was 2.27. CI was better 
for IMRT in all patients.
Lung doses
In five patients (No. 1, 2, 3, 6 and 7) with equal 
total doses mean lung dose (MLD) was lower 
using IMRT. Even though the average total 
dose in IMRT technique was higher the mean 
lung dose was still lower with IMRT. Fig. 3 
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Fig. 2. Total doses in consecutive patients, 11 is the mean 
value for all patients. 3D-CRT – total dose achieved in 3D-
CRT; IMRT – total dose achieved in IMRT
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Fig. 3. Mean lung doses and total doses in consecutive 
patients, 11 is the mean value for all patients. 3D-CRT 
– total dose achieved in 3D-CRT plan; IMRT – total dose 
achieved in IMRT plan; MLD 3D-CRT – mean lung dose in 
3D-CRT plan (value in the white box); MLD IMRT – mean 
lung dose in IMRT plan (value in the black box) 
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shows the relationship of MLD and total dose 
delivered for both studied techniques. 
Comparing lung V5 to V65 volumes at 5 Gy 
intervals we found that lung V5 (volume of 
lung receiving at least 5 Gy) was significantly 
higher for IMRT regardless of total dose. In 
Table 1 we present V5-V65 values for both 
techniques, separately for all patients and for 
patients receiving a full dose.
PTV / lung volume ratio and MLD 
relationship
We found the relationship between size of PTV 
as a percentage of lung volume and ratio of 
mean lung dose in 3D-CRT plan to mean lung 
dose in IMRT. PTV/lung volume ratio was 
0.10 for 6 patients receiving 66 Gy and 0.13 
for the whole group. Mean lung doses were 
expressed as the percentage of the total dose 
to make this comparison suitable for different 
dose level patients. In other words PTV/lung 
volume ratio was compared with 3D-CRT 
MLD/IMRT MLD ratio and the correlation 
was found. We displayed this on a graph (Fig. 
4). We can draw the conclusion that for large 
PTV IMRT can be beneficial. The bigger is 
PTV and the smaller is lung volume, the larg-
er is the size of PTV as a percentage of lung 
volume and also the greater is the advantage 
of IMRT concerning MLD. 
DISCUSSION
Our study shares the limitations of other plan-
ning studies. One of these limitations is the 
usually very limited number of patients includ-
ed. In our study, the small number of patients 
is not surprising, because patients with small 
lung volume of about 2.0 litres are treated with 
curative intent very rarely, as they are chal-
lenging for planning, especially when PTV is 
large. Observer’s (planner’s) bias may hap-
Fig. 4. Correlation of PTV/lung volume ratio to 3D-CRT 
MLD/IMRT MLD ratio in consecutive patients. Mean lung 
doses expressed by percentage of total doses
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IMRT 66 Gy 3D-CRT 66 Gy IMRT all 3D-CRT all
V5 46.5 % 35.1 % 56.5 % 47.4 %
V10 24.5 % 25.0 % 34.1 % 35.1 %
V15 19.9 % 21.6 % 27.4 % 28.3 %
V20 17.4 % 19.5 % 23.4 % 24.9 %
V25 15.5 % 17.9 % 20.8 % 22.6 %
V30 13.5 % 16.9 % 18.3 % 20.3 %
V35 11.2 % 15.5 % 15.5 % 18.0 %
V40 9.5 % 14.4 % 13.2 % 16.1 %
V45 8.1 % 13.1 % 11.4 % 13.5 %
V50 6.9 % 10.8 % 9.5 % 12.5 %
V55 5.6 % 9.1 % 7.1 % 8.8 %
V60 4.5 % 7.7 % 4.6 % 8.0 %
V65 1.5 % 4.3 % 1.7 % 4.3 %
Table 1. Mean values of lung volume receiving particular doses. From V5 (volume of lung receiving at least 
5 Gy) to V65 at 5 Gy intervals: IMRT 66 Gy – for 6 IMRT plans delivering full dose; 3D-CRT 66 Gy – for 6 3D-
CRT plans delivering full dose; IMRT all – for all IMRT plans; 3D-CRT all – for all 3D-CRT plans
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pen in such studies. There is a risk of system-
atically producing better plans for the studied 
experimental technique if a new technique is 
preferred by a planner. This is also experience 
dependent. To reduce this bias the plans were 
prepared by two physicists most experienced in 
thoracic malignancies as well as having some 
experience in IMRT planning. Each plan was 
collectively discussed and particular problems 
were solved after detailed discussion involv-
ing two physicians involved in the study. The 
weakest point of the planning studies is that 
we are not certain that the advantage shown in 
those studies represents a real clinical benefit, 
and all these studies are only the beginning of 
more extensive research. We do not know ei-
ther whether the plans realized in such studies 
are possible to be implemented in routine prac-
tice. There are ATC (Advanced Technologies 
Consortium) guidelines for the use of IMRT 
[7] to make sure that the predicted prescribed 
dose is delivered. In the lung at least two cru-
cial issues arise: one is the issue of heteroge-
neity and the other is respiratory motion. To 
minimize the effect of tissue heterogeneity ad-
vanced dose calculating algorithms should be 
used; inhomogeneity correction is essential. In 
this study the commercial algorithm of Eclipse 
v 6.5 was used, which is Pencil Beam with the 
inhomogeneity correction Modified Batho. We 
are aware that this one is not the best exist-
ing algorithm, but the same algorithm calcu-
lated doses for both 3D-CRT and IMRT plans. 
Therefore the same dose uncertainty related 
to dose calculation may happen to both IMRT 
and 3D-CRT plans. Moreover, using only 6 MV 
photon beams minimizes the dose uncertainty 
in the lung given by temporary planning sys-
tems. However, the better conformity index for 
IMRT technique indicating steeper dose follow-
off may cause bigger clinical consequences of 
any uncertainties. This problem is additionally 
magnified by respiratory motion. According 
to ATC guidelines the breathing control tech-
nique should be used for IMRT in thoracic ma-
lignancies. Respiratory gating seems the most 
suitable in lung cancer patients. In our study, 
we used free breathing CT scans for planning 
3D-CRT as well as IMRT. This means that the 
problem of target and critical structures mo-
tion, and the dose uncertainty related to this, 
was not solved.
Studies on patients with SLV and the use of 
IMRT virtually do not exist. Studied groups 
involve patients with advanced or recurrent 
disease [5], inoperable [3] or with large target 
volume [8]. The Murshed study [5] is a plan-
ning IMRT study of patients with stage III-IV 
and recurrent NSCLC previously irradiated 
with 3D-CRT. Grills et al. [3] compared four 
techniques, including similarly to our study 
3D-CRT and IMRT, in a spectrum of inoper-
able NSCLC patients. Yartsev et al. [8] analy-
sed 3D-CRT and IMRT treatment plans for 
huge PTVs in stage III NSCLC patients. In 
this work, targets included elective nodal area 
and reached as much as 2 litres.
In NSCLC radiotherapy the size matters 
but it is not only the size of the target but 
also the size, i.e. volume, of lungs. Both pa-
rameters impact on dose-volume histograms. 
Mean lung dose and V20 are proved to corre-
late with clinical risk of radiation pneumonitis 
[13]. MLD of less than 18 or 20 Gy is associ-
ated with an acceptable rate of grade 2-3 pneu-
monitis and may be used as a reference limit 
for safe clinical practice in patients with lung 
cancer [14]. There is great variation regard-
ing the risk of toxicity and the absolute cut-off 
values of V20, probably because V20 is a point 
measure and brings no information about spa-
tial dose distribution. We took V20<35% after 
Graham et al. [1]. In recent studies concern-
ing highly conformal techniques other dosim-
etric descriptors mentioned below such as V5 
are underlined.
All these dosimetric parameters help to find 
a balance between expected toxicity and de-
livering a high enough dose. In our study, the 
IMRT technique allowed higher total doses 
to be delivered, which was similar to the re-
sults of Grills et al. [3]. Mean lung dose and 
V20 were dosimetric constraints for lungs in 
both cases but threshold doses were more re-
strictive than in our study, e.g. lung V20≤25%, 
MLD≤15%. While doses to organs at risk did 
not exceed selected levels, total dose could be 
higher. The authors concluded that, keeping 
the same dose constraints for both techniques, 
IMRT may allow dose escalation especially in 
node positive cases.
The ratio of PTV to lung volume which we 
concluded is important was also noticed by 
Baisden et al. [9], who analyzing only Tomo-
Komosińska K et al. • imRT in small lung volume
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Therapy IMRT plans tested the hypothesis 
that maximum acceptable total dose to be 
delivered depends on PTV and lung volume. 
IMRT was found to be possibly beneficial in 
a group of patients with a high PTV / lung 
volume ratio. The unquestionable advantage 
of IMRT is better conformity so that there 
is better sparing of normal tissues from high 
doses. But is it really a benefit in the lung? 
With IMRT a large lung volume is irradiated 
at low doses, and we are still learning about 
the consequences of this phenomenon. Liu et 
al. [4] reported a comparison of 3D-CRT and 
IMRT concerning healthy lung tissue doses. 
V20 was reduced with IMRT. To reduce V10 
or V5 the number of beams in IMRT had to 
be decreased. How important irradiating a 
large volume at low doses might be can be 
seen in Allen’s et al. [10] study, where six out 
of thirteen patients developed fatal pneumoni-
tis even though pulmonary dose restrictions 
were kept. Mean lung dose was limited to 15 
Gy and V20 to 20% but unfortunately V5 en-
compassed almost the whole lung – mean 90% 
in patients who did not develop pneumonitis 
and mean 98.6% in those who did. According 
to Wang et al. [11] V5≥45% seems to correlate 
well with treatment related pneumonitis. In 
our study mean IMRT lung V5 was as high 
as 57%, which is too much according to those 
mentioned criteria. Six patients receiving the 
full intended total dose with both techniques 
had lower mean V5 in their IMRT plans com-
pared to all IMRT plans, and those six pa-
tients had lower mean V5 in 3D-CRT plans 
compared to all 3D-CRT plans (Figure 5). The 
V5 parameter will always be higher for treat-
ment plans with a higher number of beams, 
so it is not surprising that V5 in IMRT was 
higher than V5 in 3D-CRT. But what is inter-
esting when the planning was less challenging 
and expected total dose could be delivered, 
the volume of lung irradiated with small doses 
was smaller compared with more complicated 
cases in which we could not deliver 66 Gy.
In our study, the use of IMRT allowed 
higher total doses to be delivered. How mean-
ingful is this end-point was not validated in 
prospective phase III trials. The selection 
bias in radiotherapy dose escalation proto-
cols should be considered. Weiss et al. [12] 
reported a dose-escalation planning study 
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Fig. 5. Mean values of lung volume receiving particular doses. 
From V5 (volume of lung receiving at least 5 Gy) to V65 at 5 Gy 
intervals: IMRT 66 Gy – for 6 IMRT plans delivering full dose; 3D-
CRT 66 Gy – for 6 3D-CRT plans delivering full dose; IMRT all – for 
all IMRT plans; 3D-CRT all – for all 3D-CRT plans
performed on NSCLC patients. In this vir-
tual trial some patients were not eligible for 
higher dose levels, even though they had met 
the eligibility criteria at lower dose levels. As 
a result, the authors suggest that estimated 
outcome between patients who had been eli-
gible for higher doses and those who had met 
the selection criteria only for lower doses 
was significantly different. The authors also 
stated that interpretation and comparison of 
dose-escalation studies is a challenging task 
since some of the patients enrolled primar-
ily in the study are not even eligible for the 
lowest doses. Consequently there is selection 
bias at the very beginning and huge differ-
ences occur between patients eligible and 
ineligible for the study. In our study no pa-
tient enrolled was then excluded. Similarly, 
in our study the differences in PTV volumes 
and PTV/lung volume ratios were observed 
comparing the full dose patient group with 
the reduced total dose group in favour of the 
former. This may indicate better predict-
ed outcome for patients with smaller PTV, 
even without an attempt at dose escalation 
compared with the remainder. Despite all 
the limitations of our study we were able to 
demonstrate the potential benefit of IMRT in 
cases where small lung volume coexists with 
large PTV. We found PTV/lung volume ratio 
to be an important factor deciding the feasi-
bility of dose escalation. We suggest that for 
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NSCLC with SLV and large PTV/lung volume 
ratio IMRT with gating is worthy of further 
clinical studies. Further studies are certainly 
needed to assess the feasibility and benefit of 
such a sophisticated radiotherapy method.
CONCLUSIONS
In our planning study we demonstrated that 
patients with small lung volume may benefit 
from IMRT, especially when the dose should 
be delivered to a large target volume. What 
is also of significance, IMRT might facilitate 
dose escalation in this group of patients.
Radiotherapists should be cautious when 
implementing IMRT in small lung volume pa-
tients because little is known about the clini-
cal consequences of delivering low doses to 
a large lung volume and we still have doubt 
about the certainty of doses delivered to mov-
ing and complex targets with this highly con-
formal technique.
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